Overview

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
TYK Medicines, Inc